HCW Biologics logged its best session since May, surging 61% after unveiling progress on a next-gen version of Merck's Keytruda. Early studies showed stronger results in fighting solid tumors like pancreatic and ovarian cancer, fueling blockbuster hopes. The biotech also sees potential in age-related disease treatments.